BR112013019265A2 - uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral - Google Patents

uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral

Info

Publication number
BR112013019265A2
BR112013019265A2 BR112013019265A BR112013019265A BR112013019265A2 BR 112013019265 A2 BR112013019265 A2 BR 112013019265A2 BR 112013019265 A BR112013019265 A BR 112013019265A BR 112013019265 A BR112013019265 A BR 112013019265A BR 112013019265 A2 BR112013019265 A2 BR 112013019265A2
Authority
BR
Brazil
Prior art keywords
treatment
cerebral palsy
channel blockers
potassium channel
aminopyridine
Prior art date
Application number
BR112013019265A
Other languages
English (en)
Portuguese (pt)
Inventor
Adrian L Rabinowicz
Andrew Blight
Anthony Caggiano
Herbert R Henney Iii
Jacob D Runyan
Thomas C Wessel
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BR112013019265A2 publication Critical patent/BR112013019265A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
BR112013019265A 2011-01-28 2012-01-27 uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral BR112013019265A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437558P 2011-01-28 2011-01-28
PCT/US2012/022960 WO2012103471A1 (en) 2011-01-28 2012-01-27 Use of potassium channel blockers to treat cerebral palsy

Publications (1)

Publication Number Publication Date
BR112013019265A2 true BR112013019265A2 (pt) 2016-10-11

Family

ID=45567148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019265A BR112013019265A2 (pt) 2011-01-28 2012-01-27 uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral

Country Status (7)

Country Link
US (1) US20130030025A1 (enExample)
EP (2) EP2667869A1 (enExample)
JP (3) JP2014503596A (enExample)
AU (1) AU2012211101B2 (enExample)
BR (1) BR112013019265A2 (enExample)
CA (1) CA2825810A1 (enExample)
WO (1) WO2012103471A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
CA2909527A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
WO2017168333A1 (en) * 2016-04-02 2017-10-05 Shilpa Medicare Limited Amifampridine dihydrochloride
EP3727587A4 (en) * 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
WO2020163495A1 (en) * 2019-02-06 2020-08-13 Allergan, Inc. Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
CA3176457A1 (en) * 2020-04-08 2021-10-14 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
WO2008036294A2 (en) * 2006-09-19 2008-03-27 Northwestern University Nos inhibitors for treatment of motor deficit disorders
CA2974689C (en) * 2007-06-22 2020-02-25 The United States Of America As Represented By The Department Of Veters Affairs Inhibitors of ncca-atp channels for therapy
PE20120791A1 (es) * 2009-02-11 2012-07-08 Acorda Therapeutics Inc Composiciones y metodos para terapia prolongada con aminopiridinas
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي

Also Published As

Publication number Publication date
AU2012211101B2 (en) 2017-04-20
JP2016222685A (ja) 2016-12-28
AU2012211101A1 (en) 2013-08-15
EP2995305B1 (en) 2020-03-04
EP2667869A1 (en) 2013-12-04
JP2018197242A (ja) 2018-12-13
US20130030025A1 (en) 2013-01-31
CA2825810A1 (en) 2012-08-02
JP2014503596A (ja) 2014-02-13
WO2012103471A1 (en) 2012-08-02
EP2995305A1 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
BR112013019265A2 (pt) uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral
UA115254C2 (uk) Похідні 5-фтор-n-(піридин-2-іл)піридин-2-аміну, що містять сульфоксімінову групу
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
JO3290B1 (ar) يوراسيلات مستبدلة استبدالا ثنائيا دائريا واستخدامها
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
PH12015500988A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
UA115677C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
MX2015010128A (es) Derivados de piridazinona macrociclicos.
BR112013000596A2 (pt) piridinas e tiazinas fusionadas e seus usos.
WO2014060375A3 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
TN2016000006A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
BR112015001697A2 (pt) formulações de clomazona
IN2014CN04204A (enExample)
IN2015DN00924A (enExample)
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
PH12016501968A1 (en) Novel macrocyclic compounds
PH12015501076A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
BR112013004721A2 (pt) "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"
UA114486C2 (uk) Застосування 4-амінопіридину у лікуванні пов'язаної з інсультом сенсорно-рухової недостатності
CA2864340A1 (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]